{"protocolSection":{"identificationModule":{"nctId":"NCT02671461","orgStudyIdInfo":{"id":"CV006-004"},"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or \"Mini Strokes\"","officialTitle":"A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS- 986141 For the Prevention of Recurrent Brain Infarction in Subjects Receiving Acetylsalicylic Acid (ASA) Following Acute Ischemic Stroke or Transient Ischemic Attack"},"statusModule":{"statusVerifiedDate":"2018-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-04-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-03-31","type":"ACTUAL"},"completionDateStruct":{"date":"2017-03-31","type":"ACTUAL"},"studyFirstSubmitDate":"2016-01-29","studyFirstSubmitQcDate":"2016-01-29","studyFirstPostDateStruct":{"date":"2016-02-02","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-03-30","resultsFirstSubmitQcDate":"2018-05-16","resultsFirstPostDateStruct":{"date":"2018-06-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-12-12","lastUpdatePostDateStruct":{"date":"2018-12-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or \"mini stroke\") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stroke or TIA."},"conditionsModule":{"conditions":["Thrombosis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":16,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BMS-986141 0.8mg","type":"EXPERIMENTAL","description":"BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)","interventionNames":["Drug: BMS-986141","Drug: Aspirin"]},{"label":"BMS-986141 4.8mg","type":"EXPERIMENTAL","description":"BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets)","interventionNames":["Drug: BMS-986141","Drug: Aspirin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets)","interventionNames":["Drug: Aspirin","Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"BMS-986141","armGroupLabels":["BMS-986141 0.8mg","BMS-986141 4.8mg"]},{"type":"DRUG","name":"Aspirin","armGroupLabels":["BMS-986141 0.8mg","BMS-986141 4.8mg","Placebo"]},{"type":"OTHER","name":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28","description":"The incidence of a composite of symptomatic ischemic stroke by Day 28 and unrecognized brain infarction assessed by MRI at Day 28 was to be reported by arm in all treated participants.","timeFrame":"28 Days"},{"measure":"Percentage of Participants With Composite of Adjudicated Major Bleeding and Adjudicated Clinically Relevant Non-major (CRNM) Bleeding During the Treatment Period","description":"The percentage of participants with composite of major bleeding and CRNM bleeding was to be reported. Point estimates and 95% CIs for event rates were to be presented by treatment, together with point estimates and 95% CIs for the difference of event rates between each BMS-986141 arm and placebo.","timeFrame":"Up to 90 days"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Major Adverse Cardiovascular Events (MACE)","description":"MACE was defined as a composite of adjudicated recurrent stroke, myocardial infarction, or cardiovascular death. The percentage of treated participants experiencing these events at Day 90 was to be reported by arm.","timeFrame":"90 days"},{"measure":"Percentage of Participants With Adjudicated Symptomatic Recurrent Stroke (Including Fatal and Non-fatal)","description":"The percentage of participants with adjudicated symptomatic recurrent stroke at Day 28 was to be reported by arm for all treated participants.","timeFrame":"Day 28"},{"measure":"Percentage of Participants With Composite of Unrecognized Brain Infarction Assessed by MRI at Day 28 and MACE at Day 90","description":"The percentage of participants with unrecognized brain infarction at Day 28 and MACE at Day 90 was to be reported by arm for all treated participants.","timeFrame":"Day 90"},{"measure":"Percentage of Participants Composite of Adjudicated Recurrent Ischemic Stroke, Myocardial Infarction, or Cardiovascular Death","description":"The percentage of treated participants with composite of adjudicated recurrent ischemic stroke, myocardial infarction, or cardiovascular death was reported by arm.","timeFrame":"Day 90"}]},"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Male or female, age 18 or older\n* Must have had a very recent stroke or transient ischemic attack (\"mini stroke\") that can be confirmed by the study doctor\n* Able to be assigned to a study group no later than 48 hours after the stroke occurred\n* Has an image of the brain that confirms that the stroke was not caused by hemorrhage or other reason that could explain symptoms\n\nExclusion Criteria:\n\n* A suspicion by the study doctor that the transient ischemic attack or stroke was caused by a blood clot that formed in the heart; examples of this include history of an abnormal heart rhythm known as atrial fibrillation or a ventricular aneurysm or defect of the heart.\n* Any condition requiring treatment with an anticoagulant\n* History of intracranial hemorrhage (\"bleeding in the brain\")\n* Gastrointestinal (\"stomach or intestinal\") bleeding in the last 3 months that required treatment\n* Planned or anticipated invasive surgery or procedure during the study\n* Unable to tolerate MRI procedures.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Banner University Medical Ctr","city":"Phoenix","state":"Arizona","zip":"85006","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Hoag Memorial Hospital","city":"Newport Beach","state":"California","zip":"92658","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Local Institution","city":"Newark","state":"Delaware","zip":"19718","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"University Of Florida","city":"Gainesville","state":"Florida","zip":"32610","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"University Of Florida Hsc/Jacksonville","city":"Jacksonville","state":"Florida","zip":"32209","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Florida Hospital","city":"Orlando","state":"Florida","zip":"32803","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Intercoastal Medical Group","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Presence Saint Joseph Medical Center","city":"Joliet","state":"Illinois","zip":"64035","country":"United States","geoPoint":{"lat":41.52519,"lon":-88.0834}},{"facility":"University Of Louisville","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Local Institution","city":"Baltimore","state":"Maryland","zip":"21215","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Tufts Medical Center","city":"Boston","state":"Massachusetts","zip":"02111","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Boston Medical Center","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"St. Lukes Marion Bloch Neuroscience Institute","city":"Kansas City","state":"Missouri","zip":"64111","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Advanced Neurology Specialists","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"Local Institution","city":"Omaha","state":"Nebraska","zip":"68105","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"JFK Medical Center","city":"Edison","state":"New Jersey","zip":"08820-3947","country":"United States","geoPoint":{"lat":40.51872,"lon":-74.4121}},{"facility":"Local Institution","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Duke University Medical Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Guilford Medical Associates, Pa","city":"Greensboro","state":"North Carolina","zip":"27405","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Providence Portland Med Ctr","city":"Portland","state":"Oregon","zip":"97225","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Providence St Vincent Medical Center","city":"Portland","state":"Oregon","zip":"97225","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Oregon Health Science Univ","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Hospital of the University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"York Hospital","city":"York","state":"Pennsylvania","zip":"17403","country":"United States","geoPoint":{"lat":39.9626,"lon":-76.72774}},{"facility":"Medical University Of South Carolina","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77657,"lon":-79.93092}},{"facility":"Local Institution","city":"Memphis","state":"Tennessee","zip":"38103","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"West Virginia University","city":"Morgantown","state":"West Virginia","zip":"26505","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}},{"facility":"Local Institution","city":"Nagoya","state":"Aichi","zip":"4600001","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Local Institution","city":"Sapporo-shi","state":"Hokkaido","zip":"0608570","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Local Institution","city":"Kobe-shi","state":"Hyogo","zip":"6500047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Local Institution","city":"Sendai-shi","state":"Miyagi","zip":"982-8523","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Local Institution","city":"Hidaka-shi","state":"Saitama","zip":"3501298","country":"Japan"},{"facility":"Local Institution","city":"Fukuoka","zip":"810-0001","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Patient Recruiting","url":"http://bms.com/studyconnect/Pages/home.aspx"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"16 participants were enrolled; 15 were randomized; 14 were treated. 1 participant was not randomized because the interactive voice response system did not work at the time of enrollment","groups":[{"id":"FG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141"},{"id":"FG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days"},{"id":"FG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days"}],"periods":[{"title":"Treatment","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Administrative Reason by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Randomized, not treated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Follow-up","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Administrative Reason by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants","groups":[{"id":"BG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141"},{"id":"BG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days"},{"id":"BG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"15"}]}],"measures":[{"title":"Age, Continuous","populationDescription":"All randomized participants","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.3","spread":"9.2"},{"groupId":"BG001","value":"64.8","spread":"12.2"},{"groupId":"BG002","value":"66.7","spread":"7.6"},{"groupId":"BG003","value":"65.4","spread":"9.0"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"All randomized participants","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"10"}]}]}]},{"title":"Ethnicity (NIH/OMB)","populationDescription":"All randomized participants","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"15"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","populationDescription":"All randomized participants","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"11"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28","description":"The incidence of a composite of symptomatic ischemic stroke by Day 28 and unrecognized brain infarction assessed by MRI at Day 28 was to be reported by arm in all treated participants.","populationDescription":"Insufficient data available to perform analysis due to study termination","reportingStatus":"POSTED","timeFrame":"28 Days","groups":[{"id":"OG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141"},{"id":"OG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days"},{"id":"OG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Composite of Adjudicated Major Bleeding and Adjudicated Clinically Relevant Non-major (CRNM) Bleeding During the Treatment Period","description":"The percentage of participants with composite of major bleeding and CRNM bleeding was to be reported. Point estimates and 95% CIs for event rates were to be presented by treatment, together with point estimates and 95% CIs for the difference of event rates between each BMS-986141 arm and placebo.","populationDescription":"Insufficient data available to perform analysis due to study termination","reportingStatus":"POSTED","timeFrame":"Up to 90 days","groups":[{"id":"OG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141"},{"id":"OG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days"},{"id":"OG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Adverse Cardiovascular Events (MACE)","description":"MACE was defined as a composite of adjudicated recurrent stroke, myocardial infarction, or cardiovascular death. The percentage of treated participants experiencing these events at Day 90 was to be reported by arm.","populationDescription":"Insufficient data available to perform analysis due to study termination","reportingStatus":"POSTED","timeFrame":"90 days","groups":[{"id":"OG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141"},{"id":"OG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days"},{"id":"OG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adjudicated Symptomatic Recurrent Stroke (Including Fatal and Non-fatal)","description":"The percentage of participants with adjudicated symptomatic recurrent stroke at Day 28 was to be reported by arm for all treated participants.","populationDescription":"Insufficient data available to perform analysis due to study termination","reportingStatus":"POSTED","timeFrame":"Day 28","groups":[{"id":"OG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141"},{"id":"OG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days"},{"id":"OG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Composite of Unrecognized Brain Infarction Assessed by MRI at Day 28 and MACE at Day 90","description":"The percentage of participants with unrecognized brain infarction at Day 28 and MACE at Day 90 was to be reported by arm for all treated participants.","populationDescription":"Insufficient data available to perform analysis due to study termination","reportingStatus":"POSTED","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141"},{"id":"OG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days"},{"id":"OG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"SECONDARY","title":"Percentage of Participants Composite of Adjudicated Recurrent Ischemic Stroke, Myocardial Infarction, or Cardiovascular Death","description":"The percentage of treated participants with composite of adjudicated recurrent ischemic stroke, myocardial infarction, or cardiovascular death was reported by arm.","populationDescription":"Insufficient data available to perform analysis due to study termination","reportingStatus":"POSTED","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141"},{"id":"OG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days"},{"id":"OG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first dose until 30 days following last dose (assessed up to March 2017, approximately 6 months)","eventGroups":[{"id":"EG000","title":"Placebo","description":"Matching placebo was taken once daily. Administration was exactly the same as for BMS-986141","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":0,"otherNumAtRisk":3},{"id":"EG001","title":"BMS-986141 0.8 mg","description":"BMS-986141 0.8 mg QD for up to 28 days","deathsNumAffected":0,"deathsNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"otherNumAffected":4,"otherNumAtRisk":5},{"id":"EG002","title":"BMS-986141 4.8 mg","description":"BMS-986141 4.8 mg QD for up to 28 days","deathsNumAffected":0,"deathsNumAtRisk":7,"seriousNumAffected":1,"seriousNumAtRisk":7,"otherNumAffected":3,"otherNumAtRisk":7}],"seriousEvents":[{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]}],"otherEvents":[{"term":"Blood Potassium Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tinea Pedis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Vaginal Discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Vulvovaginal Pruritis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Viral Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Micturation Urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":5},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Muscle Spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":5},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":7}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@bms.com","phone":"Please Email:"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2015-11-19","uploadDate":"2018-03-30T15:18","filename":"SAP_000.pdf","size":4410580},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-07-07","uploadDate":"2018-03-30T15:18","filename":"Prot_001.pdf","size":3826490}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Argentina","Australia","Canada","Chile","Czech Republic","France","Germany","Hungary","Italy","Korea, Republic of","Netherlands","Romania","Spain","Sweden"]},"conditionBrowseModule":{"meshes":[{"id":"D000013927","term":"Thrombosis"}],"ancestors":[{"id":"D000016769","term":"Embolism and Thrombosis"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","asFound":"Thrombosis","relevance":"HIGH"},{"id":"M14540","name":"Recurrence","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M5485","name":"Ischemic Attack, Transient","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M7474","name":"Embolism","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}